Beyond health: why BIA is championing the biorevolution 

Linda Bedenik.png 1

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager, BioIndustry Association (BIA), discusses the concept of Deep Biotech and highlights how advancements in biotechnology offer solutions to sustainability challenges like plastic waste and fossil fuel reliance. The BIA's report, "Deep Biotech: Disruptive innovation for global sustainability" underscores the potential of biotechnology to create a sustainable UK bioeconomy and drive global change. 

In a world of ever-growing plastic waste and continued reliance on fossil fuels, we can look to biotech for solutions. Advancements like CRISPR gene editing, big data and AI analysis, genomics breakthroughs, and DNA sequencing industrialisation are driving major changes in biotechnology. 

The rise of modern industrial biotechnologies enabling us to engineer biology is leading us down a path of truly disruptive biological innovation that can tackle many of the UK’s and global sustainability threats if widely implemented.

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

We are witnessing the rise of this biorevolution. UK startups already optimize algae to transform CO2 into biofuels, use soil to grow sustainable packaging, grow meat in bioreactors, not on farms, and craft enzymes that eat plastic. Deep Biotech is about harnessing the power of biology to solve the world's toughest challenges, from climate change to pollution to resource scarcity. 

Our new report marks an exciting milestone in BIA’s growth as the UK trade association for innovative life sciences and biotech companies. It delves deeper into the impact of UK bio-innovation, showcasing the immense potential of Deep Biotech across various sectors, from energy and materials to fashion and food. We also shine a light on the hurdles Deep Biotech companies face, and how we at the BIA will champion their cause over the coming years.  

While the impact-driven nature of deep biotech is easy to grasp, its interdisciplinarity will require understanding and support across government. Elections are looming, and the task for our incoming government will be to seize the opportunity and realise biotech’s potential across our entire economy and society. With the UK’s track record of success in health biotech, we are well placed to do so, igniting the biorevolution from the medicines we take to the food we consume and the clothes we wear.  


More news and updates 

Continuity and change: Labour’s life science strategy

​​​​Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.

CEO Update - 22 April 2024

The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.

Step up and create more inclusive workplaces within the biotech sector

In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. With Deaf Awareness Week 2024 (6-12 May) fast approaching, the BIA has teamed up with its charity partner, RNID, to offer valuable resources and initiatives for creating more inclusive workplaces across the biotech sector.

Investing in life science – learnings from the first round of investments from Discovery Park Ventures

Launched in May 2022 by thriving life science community Discovery Park, Discovery Park Ventures (DPV) is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth. Initially a £1 million fund, DPV has now expanded to £3 million.

AI in life sciences: future-proofing strategies

In the final piece of the 'AI in life sciences' series, Jenny Yu, Marsh’s Life Sciences industry practice leader and experts from law firm Kennedys emphasize essential steps for life sciences companies to develop and implement a successful AI business strategy. They delve into effective management of outcomes from AI technologies and strategies to mitigate potential risks.

CEO Update - 15 April 2024

In case you missed it last week, post-Brexit border paperwork and inspections have been postponed for the life sciences sector, thanks to BIA work. Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

CEO Update - 8 April 2024

I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.

How to build a high-performance life science team

In this blog, Olivia Fletcher-Hogg, Programme Manager at Pioneer Group, provides actionable insights for building high-performance teams in the life sciences and biotech sector, from fostering a positive work culture to empowering employee development.

AI in life sciences: regulating AI technologies and the product liability implications

Recent regulatory developments in the EU and UK suggest a proactive stance on governing AI technologies, with the EU introducing comprehensive regulations and the UK proposing reforms to align with emerging digital technologies.

CEO Update - 25 March 2024

I’m delighted to be opening PULSE this morning. It is a free three-day leadership and entrepreneurship training programme for up-and-coming life sciences entrepreneurs that we’ve developed and delivered with the Francis Crick Institute. Read on for the latest on EU biotech initiatives, Biosecurity Leadership Council and boost for UK cell and gene therapy.


More within